View Item 

Show simple item record

Uses and Abuses of Tumor Markers in the Diagnosis, Monitoring, and Treatment of Primary and Metastatic Breast Cancer

dc.contributor.authorHenry, N. Lynn
dc.contributor.authorHayes, Daniel F.
dc.date.accessioned2017-12-15T16:47:00Z
dc.date.available2017-12-15T16:47:00Z
dc.date.issued2006-06
dc.identifier.citationHenry, N. Lynn; Hayes, Daniel F. (2006). "Uses and Abuses of Tumor Markers in the Diagnosis, Monitoring, and Treatment of Primary and Metastatic Breast Cancer." The Oncologist 11(6): 541-552.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/139922
dc.publisherAlphaMed Press
dc.publisherWiley Periodicals, Inc.
dc.subject.otherEstrogen receptor
dc.subject.otherTumor marker
dc.subject.otherPredictive factor
dc.subject.otherPrognostic factor
dc.subject.otherHer‐2/neu
dc.subject.otherBreast cancer
dc.titleUses and Abuses of Tumor Markers in the Diagnosis, Monitoring, and Treatment of Primary and Metastatic Breast Cancer
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Internal Medicine, Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139922/1/onco0541.pdf
dc.identifier.doi10.1634/theoncologist.11-6-541
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceSlamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER‐2/neu oncogene. Science 1987; 235: 177 – 182.
dc.identifier.citedreferenceHarvey JM, Clark GM, Osborne CK et al. Estrogen receptor status by immunohistochemistry is superior to the ligand‐binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474 – 1481.
dc.identifier.citedreferenceAllard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897 – 6904.
dc.identifier.citedreferencePaik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen‐treated, node‐negative breast cancer. N Engl J Med 2004; 351: 2817 – 2826.
dc.identifier.citedreferenceAltman DG, Lausen B, Sauerbrei W et al. Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829 – 835.
dc.identifier.citedreferenceCristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781 – 791.
dc.identifier.citedreferenceGelber RD, Bonetti M, Castiglione‐Gertsch M et al. Tailoring adjuvant treatments for the individual breast cancer patient. Breast 2003; 12: 558 – 568.
dc.identifier.citedreferenceFisher B, Dignam J, Wolmark N et al. Tamoxifen and chemotherapy for lymph node‐negative, estrogen receptor‐positive breast cancer. J Natl Cancer Inst 1997; 89: 1673 – 1682.
dc.identifier.citedreferenceFisher B, Costantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node‐negative breast cancer who have estrogen‐receptor‐positive tumors. N Engl J Med 1989; 320: 479 – 484.
dc.identifier.citedreferenceMcShane LM, Altman DG, Sauerbrei W et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93: 387 – 391.
dc.identifier.citedreferenceYamauchi H, Stearns V, Hayes DF. The role of c‐erbB‐2 as a predictive factor in breast cancer. Breast Cancer 2001; 8: 171 – 183.
dc.identifier.citedreferenceAdjuvant! Online breast cancer help files: prognostic estimates. 2006. https://www.adjuvantonline.com/breathelp0306/breastindex.html. Accessed February 17, 2006.
dc.identifier.citedreferenceEllis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB‐1‐ and/or ErbB‐2‐positive, estrogen receptor‐positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808 – 3816.
dc.identifier.citedreferenceMuss HB, Thor AD, Berry DA et al. c‐erbB‐2 expression and response to adjuvant therapy in women with node‐positive early breast cancer. N Engl J Med 1994; 330: 1260 – 1266.
dc.identifier.citedreferenceThor AD, Berry DA, Budman DR et al. erbB‐2, p53, and efficacy of adjuvant therapy in lymph node‐positive breast cancer. J Natl Cancer Inst 1998; 90: 1346 – 1360.
dc.identifier.citedreferencePiccart‐Gebhart MJ, Procter M, Leyland‐Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2‐positive breast cancer. N Engl J Med 2005; 353: 1659 – 1672.
dc.identifier.citedreferenceRomond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2‐positive breast cancer. N Engl J Med 2005; 353: 1673 – 1684.
dc.identifier.citedreferenceSeidman AD, Berry D, Cirrincione C et al. CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1‐hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 2004; 22: 512a.
dc.identifier.citedreferencePaik S, Shak S, Tang G et al. Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B‐14 and chemotherapy in NSABP study B‐20. Breast Cancer Res Treat 2004; 88: 24a.
dc.identifier.citedreferenceClinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996; 14: 2843 – 2877.
dc.identifier.citedreferenceHayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456 – 1466.
dc.identifier.citedreferenceMcShane LM, Altman DG, Sauerbrei W et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93: 387 – 391.
dc.identifier.citedreferenceAmerican Cancer Society. Cancer Facts and Figures, 2005. Available at http://www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf. Accessed March 10, 2005.
dc.identifier.citedreferencePeto R, Boreham J, Clarke M et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet 2000; 355: 1822.
dc.identifier.citedreferenceBerry DA, Cronin KA, Plevritis SK et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784 – 1792.
dc.identifier.citedreferenceBast RC Jr, Ravdin P, Hayes DF et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865 – 1878.
dc.identifier.citedreferenceHammond ME, Fitzgibbons PL, Compton CC et al. College of American Pathologists Conference XXXV: solid tumor prognostic factors‐which, how and so what? Summary document and recommendations for implementation. Arch Pathol Lab Med 2000; 124: 958 – 965.
dc.identifier.citedreferenceClinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996; 14: 2843 – 2877.
dc.identifier.citedreferenceBast RC Jr, Ravdin P, Hayes DF et al. Errata: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 4185 – 4188.
dc.identifier.citedreferenceCobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti‐HER2 monoclonal antibody in women who have HER2‐overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639 – 2648.
dc.identifier.citedreferenceSlamon DJ, Leyland‐Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783 – 792.
dc.identifier.citedreferenceMass RD, Press MF, Anderson S et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005; 6: 240 – 246.
dc.identifier.citedreferenceHayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456 – 1466.
dc.identifier.citedreferenceStearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat 1998; 52: 239 – 259.
dc.identifier.citedreferenceMcGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary‐node‐negative breast cancer. N Engl J Med 1992; 326: 1756 – 1761.
dc.identifier.citedreferenceGasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node‐negative breast cancer patients. J Natl Cancer Inst 1993; 85: 1206 – 1219.
dc.identifier.citedreferenceHayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: when is “statistically significant” clinically useful? Breast Cancer Res Treat 1998; 52: 305 – 319.
dc.identifier.citedreferenceIsaacs C, Stearns V, Hayes DF. New prognostic factors for breast cancer recurrence. Semin Oncol 2001; 28: 53 – 67.
dc.identifier.citedreferenceFisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P‐1 Study. J Natl Cancer Inst 1998; 90: 1371 – 1388.
dc.identifier.citedreferenceKnight WA, Livingston RB, Gregory EJ et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 1977; 37: 4669 – 4671.
dc.identifier.citedreferenceHayes DF. Do we need prognostic factors in nodal‐negative breast cancer? Arbiter. Eur J Cancer 2000; 36: 302 – 306.
dc.identifier.citedreferenceEarly Breast Cancer Trialists’ Collaborative Group (EBCTG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15‐year survival: an overview of the randomised trials. Lancet 2005; 365: 1687 – 1717.
dc.identifier.citedreferenceMcGuire WL, Chamness GC, Costlow ME et al. Steroids and human breast cancer. J Steroid Biochem 1975; 6: 723 – 727.
dc.identifier.citedreferenceAllegra JC, Lippman ME, Thompson EB et al. Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer. Eur J Cancer 1980; 16: 323 – 331.
dc.identifier.citedreferenceDressler LG, Berry DA, Broadwater G et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin‐based therapy in node‐positive breast cancer patients. J Clin Oncol 2005; 23: 4287 – 4297.
dc.identifier.citedreferencePerez EA, Suman VJ, Davidson NE et al. HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. J Clin Oncol 2004; 22: 567a.
dc.identifier.citedreferencePress MF, Hung G, Godolphin W et al. Sensitivity of HER‐2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54: 2771 – 2777.
dc.identifier.citedreferenceJacobs TW, Gown AM, Yaziji H et al. Specificity of HercepTest in determining HER‐2/neu status of breast cancers using the United States Food and Drug Administration‐approved scoring system. J Clin Oncol 1999; 17: 1983 – 1987.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco0541.pdf
Size:
300.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.